DSIP (delta sleep-inducing peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a nonapeptide first isolated in 1977 by Monnier and colleagues from the cerebral venous blood of rabbits during slow-wave (delta) sleep induction experiments. It is found endogenously in both brain and peripheral tissues including pituitary, hypothalamus, and plasma, with levels showing circadian variation.
Monnier et al. (1977, Science) reported isolating a factor from dialysate of venous blood from the cerebral sinus of sleeping rabbits that, when infused into recipient rabbits, induced sleep characterised by increased delta-wave (slow-wave) activity. The active peptide was isolated, sequenced, and named delta sleep-inducing peptide. This discovery established a framework for understanding endogenous sleep-promoting substances distinct from adenosine and cytokine-mediated sleep regulation.
Subsequent work demonstrated DSIP's presence in human cerebrospinal fluid, plasma, and various brain regions, with a circadian pattern showing higher concentrations during sleep phases. This endogenous rhythm supports a physiological role in sleep-wake cycle regulation.
The sleep-modulating effects of DSIP have been investigated in human studies. Graf et al. (1984) and Schneider-Helmert (1984) reported that DSIP infusion in poor sleepers improved sleep architecture, increasing slow-wave sleep and reducing sleep onset latency. Effects were not seen in good sleepers, suggesting that DSIP modulates rather than forces sleep and may correct disrupted sleep rather than acting as a sedative per se.
The mechanism is not fully characterised, but evidence points to interactions with multiple neurotransmitter systems. DSIP modulates serotonergic neurotransmission (relevant to sleep stage regulation), and appears to interact with GABA-A receptor function, potentially potentiating GABAergic tone during sleep induction. Unlike hypnotic drugs, DSIP does not appear to bind benzodiazepine or barbiturate sites on GABA-A receptors.
DSIP has been shown to modulate the HPA axis (hypothalamic-pituitary-adrenal axis). In rodent stress models, DSIP administration reduces corticosteroid stress responses and blunts ACTH secretion. This stress-buffering property is studied in the context of stress-induced sleep disruption and anxiety. The interaction between sleep architecture disruption and HPA dysregulation (a common feature of insomnia and PTSD models) makes DSIP a useful research tool for studying sleep-stress axis interactions.
Russian research groups have published data on DSIP in opioid withdrawal models. Preclinical studies show DSIP reduces withdrawal symptom severity in morphine-dependent animals. Clinical research in Russia and Eastern Europe has examined DSIP in alcohol and opioid withdrawal protocols, reporting reductions in withdrawal severity scores and improved sleep quality during abstinence. The mechanism may relate to normalisation of disrupted HPA function and restoration of sleep architecture during withdrawal states.
Beyond CNS activity, DSIP has demonstrated antioxidant properties in cellular studies, reducing reactive oxygen species and protecting cells from oxidative damage. Anti-tumour effects have been reported in certain rodent cancer models, though the mechanism is not established. These peripheral activities suggest DSIP has pleiotropic biological roles beyond its sleep-promoting function.
